Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Company Reiterates 2008 Earnings Guidance and Introduces Q1 2008 Guidance

FRAZER, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2007 sales of $1.727 billion, compared to sales of $1.720 billion for 2006, exceeding the company's previously issued guidance. Basic loss per common share for the full year 2007 was $2.88. Excluding the previously announced settlement reserve, amortization expense and certain other items, basic adjusted income per common share for the full year was $4.64, which compares to $5.22 for 2006 and exceeds the high end of the company's earnings guidance range of $4.45 to $4.55.

2007 central nervous system (CNS) franchise sales increased 16 percent to $909.4 million compared to 2006 and the pain franchise reported strong sales of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. Sales of other products increased 15 percent to $305.3 million.

"We delivered strong performance across all aspects of our business in 2007. We launched AMRIX, filed three NDAs, introduced three new Phase 1 programs, and delivered greater sales and earnings than expected," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We believe that 2008 will mark the beginning of a new phase of growth for the company with a full year of AMRIX sales, the potential for approval of TREANDA and expanded indications for FENTORA, and continued progress on the clinical development plan for NUVIGIL. In fact, the NUVIGIL program is already off to a great start with promising results from our first Phase 2 study in the treatment of schizophrenia."

The company is reiterating its guidance for 2008 total sales of $1.80 - $1.85 billion, adjusted net income of $344 - $351 million and its basic adjusted income per common share guidance of $5.10 - $5.20.

Cephalon is introducing first quarter 2008 sales guidance of $435 - $445 mil
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... The agenda for Arrowhead’s 201...hich is set to take place on February 22-24, 2010 ... day conference we will highlight key issues in fo... share their experiences. , ... agenda for Arrowhead’s 2010 Personalized M...
(Date:11/5/2009)...RSBURG, Md., Nov. 5 GenV...ncial results for the third quarter ended Septembe...lion ($0.04 per share) for the three months ended ...million ($0.08 per share) in the comparable quarte... 2009, GenVec,s net loss was $14.1 million ($0.15 ...
(Date:11/5/2009)...PANY, N.J., Nov. 5 DSM Pharmaceuti...nufacturing alliance with Galenix, Saint Jean D,Il...rcial scale manufacturing partner for Galenix comm...alenix will collaborate on business development op...hnologies, based on the strength of Galenix in dru...
(Date:11/5/2009)... CORDOVA, Calif., Nov. 5 ...upplier of innovative products for processing and ...or the first quarter of fiscal 2010. ,, For the...orted revenues of $5.2 million, a 15 percent incre...rter a year ago. The Company said the key contribu...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
... Mass., Oct. 8 Inverness Medical,Innovations (Ame... a Scheme,Implementation Agreement with Panbio Ltd...ecurities Exchange, under which it is proposed tha...in Panbio for AUD 0.65 cash,per share. The propose...,Panbio at approximately AUD 41 million, or approx...
... HEIGHTS, N.J., Oct. 8 Clinsys Clinical,Research,... organization,today announced the relocation of it...y,s significant growth and plans for future expans...ter, New Jersey. "Our new headquarters, combined ..., North Carolina and Dusseldorf, Germany, offers m...
...October 8 Innovation in the pharma industry is,no... once small molecule,research provided the mainsta...making their presence felt. While the range of gen...s are providing the current focus for novel,discov...cules; the rules,for their development are differe...
Other Biology Technology:Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters 2Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes 2
(Date:11/8/2009)... WEST LAFAYETTE, Ind. - Researchers at Purdue Univ...g damaged nerve fibers in spinal cord injuries usi...ood shortly after an accident. , The synthetic "...t 60 nanometers in diameter, or roughly 100 times ... Researchers have been studying how to deliver dru...
(Date:11/6/2009)...ee-dwelling ants generally live in harmony with th... when they run out of space in their trees of choi...ees. , The research, published in the November i... document that ants bore into live trees, and it r...between ants and plants. , Ants and certain spec...
(Date:11/5/2009)...nt State University has been awarded a training gr...ience Foundation under its Integrative Graduation ...his is the first IGERT grant to be awarded to Kent...can Recovery and Reinvestment Act of 2009, runs th...hat focuses on environment aquatic resource sensin...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Sysmex America Debuts High end Sample Management System During AACC 52129 1Sysmex America Debuts High end Sample Management System During AACC 52129 2Sysmex America Debuts High end Sample Management System During AACC 52129 3Understanding Managed Markets 3A Effective Market Research Structures 26 Activities to Maximize Payer Access 26 Insights 13093 1Understanding Managed Markets 3A Effective Market Research Structures 26 Activities to Maximize Payer Access 26 Insights 13093 2Internet May Be Newest Venue for Teen Tobacco Exposure 52122 1Internet May Be Newest Venue for Teen Tobacco Exposure 52122 2Internet May Be Newest Venue for Teen Tobacco Exposure 52122 3
...Presbycusis, or age-related hearing loss, accounts...ome people lose their hearing as they get older bu... answer may be in a study released online in the j...is available online at http://hmg.oxfordjournals....r and largest genome-wide association study for ag...
...g widespread consumption advisories and uncertaint...at. Now researchers at North Carolina State Univer...sts and regulators around the country predict whic...levels a breakthrough that should help officials ...visories for specific water bodies and fish specie...
...oration of Stanford University,s Woods Institute f... World Wildlife Fundhas been awarded a two-year, $... Foundation to develop a software program for mapp...by temperate marine ecosystems. , Called Marine I...and Tradeoffs), the proposed software will give po...
Other Biology News:House Ear Institute, TGen and Belgian researchers identify gene in age-related hearing loss 2New model predicts hot spots for mercury in fish 2Natural Capital Project to develop conservation software 2
...2000 instrument can be used as a fully functional,...ger Software provides the means to record and tabu...hese data can then be copied and pasted into comme...Excel or Lotus 123, or into a curve-fitting progra...
Corning Cryo Box, 81 Position, 4-5 ml, Non-Sterile from Sigma-Aldrich
...oarray Kit (V2), 2 x 11K will enable researchers t...housands of yeast genes and identify gene activity...array contains sequences representing probes repre...Saccharomyces cerevisiae, sourced from the Sacchar...
...e offers an intuitive, easy-to-use operating envir...data handling, and integration with regulatory com...ude data acquisition, re-analysis, custom reports,...k environments. LCMSsolutions assistant bar provid...
Biology Products: